Carfilzomib 10 mg Powder for solution for injection/infusion Vial

Product Overview: Carfilzomib 10 mg Powder for Solution for Injection/Infusion

Carfilzomib 10 mg Powder for Solution for Injection/Infusion, marketed under the brand name Kyprolis, is a potent medication used in the treatment of multiple myeloma. Developed by Amgen, this injectable drug plays a crucial role in modern oncology by targeting cancer cells through a specific mechanism of action.

Multiple myeloma is a cancer of plasma cells, a type of white blood cell found in the bone marrow. Carfilzomib is a proteasome inhibitor, meaning it works by blocking the proteasome, an enzyme complex within cells that breaks down unneeded or damaged proteins. By inhibiting the proteasome, Carfilzomib causes an accumulation of these proteins inside cancer cells, leading to their death. This targeted approach helps to control disease progression and improve patient outcomes.

This medication is typically used in combination with other anti-cancer drugs, offering a comprehensive treatment strategy for patients who have received at least one prior therapy for multiple myeloma.

Benefits of Use

• Targeted therapy for multiple myeloma: Specifically inhibits the proteasome, a key pathway for cancer cell survival.
• Effective in relapsed or refractory multiple myeloma: Demonstrated efficacy in patients who have not responded to or have relapsed after previous treatments.
• Improved progression-free survival: Helps to extend the period during which the disease does not worsen.
• Often used in combination regimens: Enhances the overall effectiveness of multiple myeloma treatment when combined with other agents.

How to Use

1. Carfilzomib 10 mg Powder for Solution for Injection/Infusion is an intravenous medication that must be prepared and administered by a qualified healthcare professional.
2. The powder must be reconstituted with Sterile Water for Injection, followed by further dilution with 5% Dextrose Injection.
3. The exact dosage, infusion rate, and treatment schedule will be determined by the treating physician based on the patient's condition, body surface area, and the specific treatment regimen.
4. Administration typically occurs over a specific duration (e.g., 10 minutes or 30 minutes) on scheduled days.
5. Patients should receive adequate hydration before and after Carfilzomib administration to minimize the risk of renal toxicity and tumor lysis syndrome.

Caution & Warnings

• Cardiovascular Events: Patients may experience heart failure, myocardial ischemia, or pulmonary hypertension. Regular monitoring of cardiac function is essential.
• Pulmonary Toxicity: Cases of acute respiratory distress syndrome (ARDS) and other pulmonary complications have been reported.
• Infusion Reactions: Reactions such as fever, chills, dyspnea, or flushing can occur during or within 24 hours of infusion.
• Hepatic Toxicity: Liver enzyme elevations and liver failure have been observed. Liver function should be monitored.
• Thrombocytopenia: A decrease in platelet count is common, increasing the risk of bleeding.
• Renal Toxicity: Acute renal failure can occur. Adequate hydration is crucial.
• Tumor Lysis Syndrome (TLS): This serious complication can result from rapid breakdown of cancer cells, requiring careful management.
• Thrombotic Microangiopathy (TMA): Cases of TMA, including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), have been reported.
• Posterior Reversible Encephalopathy Syndrome (PRES): A neurological disorder that can cause seizures, headaches, and visual disturbances.
• Embryo-Fetal Toxicity: Carfilzomib can cause fetal harm. Pregnant women or women of childbearing potential should use effective contraception.
• Peripheral Neuropathy: While less common than with some other proteasome inhibitors, peripheral neuropathy can occur.

Ingredients

Active Ingredient: Carfilzomib

Excipients: Betadex sulfobutyl ether sodium, Citric acid, Sodium citrate.

Product Details

• Brand Name: Kyprolis
• Manufacturer: Amgen
• Dosage Form: Powder for Solution for Injection/Infusion
• Strength: 10 mg per vial
• Package Type: Single-use Vial
• Storage: Store refrigerated at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze.